http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#Head
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#provenance
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#pubinfo
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion
http://purl.obolibrary.org/obo/DOID_2377
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2377
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00108
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
http://www.w3.org/2000/01/rdf-schema#label
tysabri is an integrin receptor antagonist indicated for treatment of multiple sclerosis ms tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri 1 1 5 1 crohn s disease cd tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a 1 2 important limitations in cd tysabri should not be used in combination with immunosuppressants or inhibitors of tnf a 1 2 tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri see warnings and precautions 5 1 tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a tysabri should not be used in combination with immunosuppressants e g 6 mercaptopurine azathioprine cyclosporine or methotrexate or inhibitors of tnf a see warnings and precautions 5 1
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00108
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#provenance
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#pubinfo
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig
http://purl.org/nanopub/x/hasSignature
Ybo5naNNuodmPHxEiH+7ce12zhztxiN+LgdRRPGU4Ozccij6MJANLZQ7exrPZxkZB/5I4ce6KQwK1GZ9/qzQHSMQXRNVS5IOfImoF9FkkGbs5qJx7TJpMBhOxdpqu0nGKRLGUdaB6yokD+ybGnZN6FG6JKm+RNKlOcILXs5rHNI=
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
http://purl.org/dc/terms/created
2021-07-03T15:13:05.636+02:00
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs